Aerie Pharmaceuticals (NASDAQ:AERI) Price Target Cut to $41.00 by Analysts at HC Wainwright
Aerie Pharmaceuticals (NASDAQ:AERI) had its target price reduced by HC Wainwright from $55.00 to $41.00 in a research report released on Thursday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other brokerages have also issued reports on AERI. Needham & Company LLC reissued a buy rating and set a $54.00 target price on shares of Aerie Pharmaceuticals in a research note on Friday, October 25th. BidaskClub raised shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, October 30th. JMP Securities lowered their target price on shares of Aerie Pharmaceuticals from $58.00 to $52.00 and set a market outperform rating for the company in a research note on Thursday, August 8th. Mizuho reissued ...